Fig. 4From: Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi ArabiaBootstrap Distribution of Cost-Effectiveness: Risankizumab vs. Adalimumab under Weekly Dosing Assumption for AdalimumabBack to article page